Mundipharma International Ltd:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C0497)
◆英語タイトル:Mundipharma International Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0497
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年7月
◆ページ数:78
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Mundipharma International Ltd (Mundipharma) engages in the research and development of products for the treatment pain management, respiratory, cancer and inflammatory conditions. The company commercializes and launches products within Europe and rest of the world. Mundipharma offers its products through its network of subsidiaries, independent associated companies, partners and joint ventures. The company’s network includes Napp Pharmaceuticals, Norpharma and the Mundipharma independent associated companies. The company provides its services to patients, healthcare professionals and health systems worldwide. It has operations in Australia, Japan, New Zealand, Russia, Singapore, Philippines, South Africa, South Korea, Canada, China and USA. Mundipharma is headquartered in Cambridge, the UK.

Mundipharma International Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Mundipharma International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Mundipharma International Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Mundipharma Acquires Rights to CAP7.1 from CellAct 15
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 16
Purdue Pharma Acquires Rights to VM-902A from VM Pharma 17
Venture Financing 18
Kolltan Pharma Raises US$60 Million In Series D Financing 18
Partnerships 20
Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 20
Mundipharma Expands Agreement with Kolon Life Science 21
University of Texas Health Science Center Enters into Co-Development Agreement with Purdue Pharma 22
University of Nebraska Medical Center and Purdue Pharma Enter into Agreement 23
Mundipharma Enters into Distribution Agreement with Shionogi 24
Purdue Pharma to Form Joint Venture with AnaBios 25
Eisai Enters into Agreement with Purdue Pharma 26
Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 27
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 28
ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 30
Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101 31
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 33
Licensing Agreements 35
Mundipharma Enters into Licensing Agreement with Neovii Pharma 35
Mundipharma Enters into Licensing Agreement with Starpharma Holding 36
Mundipharma Enters into Licensing Agreement with Grunenthal 37
Mundipharma Enters into Licensing Agreement with Paion 38
Mundipharma Enters into Licensing Agreement with APR Applied Pharma Research 39
Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 40
Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 41
Purdue Pharma Canada Enters into Licensing Agreement with Helsinn Group 42
Mundipharma Enters into Licensing Agreement with Vectura for VR2076 43
Purdue Pharma Enters into Licensing Agreement with Exicure 44
Purdue Pharma Enters into Licensing agreement with AnaBios 45
Purdue Pharma Enters Into Licensing Agreement With Medical Developments 46
Mundipharma International Enters into Licensing Agreement with Orexo 47
Helsinn Signs Licensing Agreement with Purdue Pharma Canada 48
Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 49
Mundipharma International Enters into Licensing Agreement with Helsinn 50
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 51
SkyePharma Enters into Option Agreement with Mundipharma 52
Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 53
Mundipharma Enters into Licensing Agreement with Medical Developments for Penthrox 55
Mundipharma Enters into Licensing Agreement with Helsinn 56
Helsinn Enters into Licensing Agreement with Mundipharma for Anamorelin 57
Helsinn Enters into Licensing Agreement with Mundipharma for NEPA 58
Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 59
Mundipharma Enters into Licensing Agreement with Genewel for Medifoam 61
Mundipharma Enters Into Licensing Agreement With Grunenthal 62
Helsinn Enters Into Licensing Agreement With Mundipharma For Netupitant-Palonosetron Fixed Dose Combination 63
Mundipharma Plans to Extend Licensing Agreement with Genewel for Medifoam 64
Mundipharma Enters Into Licensing Agreement With Shionogi 65
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 66
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 67
Asset Transactions 68
Fidelio Healthcare Partners to Acquire Production Site and Facilities from Mundipharma 68
Acquisition 69
Mundipharma Acquires Tolmar Australia 69
Mundipharma International Ltd – Key Competitors 70
Mundipharma International Ltd – Key Employees 71
Mundipharma International Ltd – Locations And Subsidiaries 72
Head Office 72
Other Locations & Subsidiaries 72
Joint Venture 75
Recent Developments 76
Corporate Communications 76
Dec 13, 2017: Dr Alberto Martinez appointed President and CEO of Mundipharma International 76
Dec 05, 2017: Mundipharma appoints Chief Information Officer 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Mundipharma International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Mundipharma International Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Mundipharma International Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Mundipharma Acquires Rights to CAP7.1 from CellAct 15
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 16
Purdue Pharma Acquires Rights to VM-902A from VM Pharma 17
Kolltan Pharma Raises US$60 Million In Series D Financing 18
Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 20
Mundipharma Expands Agreement with Kolon Life Science 21
University of Texas Health Science Center Enters into Co-Development Agreement with Purdue Pharma 22
University of Nebraska Medical Center and Purdue Pharma Enter into Agreement 23
Mundipharma Enters into Distribution Agreement with Shionogi 24
Purdue Pharma to Form Joint Venture with AnaBios 25
Eisai Enters into Agreement with Purdue Pharma 26
Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 27
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 28
ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 30
Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101 31
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 33
Mundipharma Enters into Licensing Agreement with Neovii Pharma 35
Mundipharma Enters into Licensing Agreement with Starpharma Holding 36
Mundipharma Enters into Licensing Agreement with Grunenthal 37
Mundipharma Enters into Licensing Agreement with Paion 38
Mundipharma Enters into Licensing Agreement with APR Applied Pharma Research 39
Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 40
Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 41
Purdue Pharma Canada Enters into Licensing Agreement with Helsinn Group 42
Mundipharma Enters into Licensing Agreement with Vectura for VR2076 43
Purdue Pharma Enters into Licensing Agreement with Exicure 44
Purdue Pharma Enters into Licensing agreement with AnaBios 45
Purdue Pharma Enters Into Licensing Agreement With Medical Developments 46
Mundipharma International Enters into Licensing Agreement with Orexo 47
Helsinn Signs Licensing Agreement with Purdue Pharma Canada 48
Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 49
Mundipharma International Enters into Licensing Agreement with Helsinn 50
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 51
SkyePharma Enters into Option Agreement with Mundipharma 52
Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 53
Mundipharma Enters into Licensing Agreement with Medical Developments for Penthrox 55
Mundipharma Enters into Licensing Agreement with Helsinn 56
Helsinn Enters into Licensing Agreement with Mundipharma for Anamorelin 57
Helsinn Enters into Licensing Agreement with Mundipharma for NEPA 58
Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 59
Mundipharma Enters into Licensing Agreement with Genewel for Medifoam 61
Mundipharma Enters Into Licensing Agreement With Grunenthal 62
Helsinn Enters Into Licensing Agreement With Mundipharma For Netupitant-Palonosetron Fixed Dose Combination 63
Mundipharma Plans to Extend Licensing Agreement with Genewel for Medifoam 64
Mundipharma Enters Into Licensing Agreement With Shionogi 65
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 66
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 67
Fidelio Healthcare Partners to Acquire Production Site and Facilities from Mundipharma 68
Mundipharma Acquires Tolmar Australia 69
Mundipharma International Ltd, Key Competitors 70
Mundipharma International Ltd, Key Employees 71
Mundipharma International Ltd, Subsidiaries 72
Mundipharma International Ltd, Joint Venture 75

List of Figures
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Mundipharma International Ltd, Medical Devices Deals, 2012 to YTD 2018 11

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Mundipharma International Ltd:製薬・医療:M&Aディール及び事業提携情報(Mundipharma International Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆